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Abstract To study the regulatory mechanism of gp91phox gene
expression in eosinophils, we transiently transfected eosinophil-
committed HL-60-C15 cells with gp91phox promoter constructs,
and identified a negative element from bp 3267 to 3246 of the
gp91phox gene, the deletion of which caused an 83% increase in
promoter activity. Electrophoresis mobility shift assays demon-
strated GATA-3 binds to the GATA consensus site from bp
3256 to 3250. An 81% increment in promoter activity was
obtained when a mutation was introduced in the GATA-3 binding
site of the bp 3267 to +12 construct, which is comparable to that
of the bp 3245 to +12 construct. We therefore conclude that
GATA-3 specifically binding to the GATA site negatively
regulates the expression of the gene in HL-60-C15 cells.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Eosinophils, like other professional phagocytes (neutro-
phils, monocytes and macrophages), are involved in host de-
fense against invaders, especially parasites, by producing
superoxide anion [1,2]. The cells are also involved in allergic
responses and killing of tumor cells [3]. When the cells are
challenged with a variety of stimuli, the phagocyte NADPH
oxidase becomes rapidly active to generate reactive oxygen
intermediates [4,5]. Any defects in a key component of
NADPH oxidase, gp91phox, lead in approximately two-thirds
of cases to chronic granulomatous diseases (CGDs) [6].
The gp91phox gene is exclusively expressed in phagocytic
cells di¡erentiated beyond the promyelocytic stage and B lym-
phocytes [7]. It has been reported that in£ammatory media-
tors such as lipopolysaccharide, tumor necrosis factor K, gran-
ulocyte-macrophage colony-stimulating factor and interferon-
Q (IFN-Q) augment the transcription of the gp91phox gene [8,9].
To date, a number of regulatory cis-elements in the proximal
promoter of the gp91phox gene and trans-acting factors includ-
ing IRF-1, IRF-2, CP1, BID, TF1phox and PU.1 as activators,
and CDP as a repressor have been identi¢ed in non-eosino-
philic lineages [10^13]. We discovered a novel CGD patient
with normal superoxide-generating activity in eosinophils
[14,13], suggesting an eosinophil-speci¢c regulatory mecha-
nism for the gp91phox gene. To understand the eosinophil-spe-
ci¢c transcriptional mechanism for the gene, we used eosino-
phil-committed HL-60-C15 cells that express the gp91phox
gene, and identi¢ed a GATA binding site as a negative cis-
element of the gp91phox promoter and GATA-3 as a repressor.
GATA-3 is expressed in eosinophil lineages but not in other
phagocytic or B lymphocytic lineages [15,16]. Accordingly, the
eosinophil lineage uses, at least in part, its own mechanisms
for the inhibition of gp91phox gene expression.
2. Materials and methods
2.1. Construction of plasmid for promoter analysis
Various deletive gp91phox promoter constructs were prepared from
a plasmid containing the human gp91phox gene sequence from bp
3487 to +12 inserted into a polycloning site of a promoterless luci-
ferase vector pGVB2 (Toyoink, Tokyo) as follows. The plasmid was
linearized by SacI, and the 5P overhang sequence was exposed by XhoI
at its 5P end to make the site sensitive to exonuclease III. The plasmid
DNA extracted by phenol/chloroform was precipitated with isopro-
panol, and dissolved into 100 Wl of exonuclease III bu¡er (50 mM
Tris-HCl, pH 8.0, 100 mM NaCl, 5 mM MgCl2, 10 mM 2-mercap-
toethanol). 1 Wl of exonuclease III (Takara, Japan) was added to the
DNA solution and the mixture was immediately placed in a water
bath incubator kept at 37‡C. During the incubation with exonuclease
III, an aliquot of 10 Wl of the above solution was taken at 0.5 min and
every 2 min thereafter until 20.5 min into an Eppendorf tube contain-
ing 10 Wl of ice-cold MB nuclease bu¡er (40 mM Na-acetate, pH 4.5,
100 mM NaCl, 2 mM ZnCl2, 10% glycerol) and immediately placed
on dry ice. The mixture was incubated at 65‡C for 5 min for the
inactivation of the exonuclease III, cooled on ice for 2 min, and
incubated with 10 units of MB nuclease at 37‡C for 30 min to
make blunt ends at both sides of linearized and digested plasmid
DNA. The plasmid DNA was extracted, precipitated as above and
resuspended in 9 Wl of T4 DNA ligation bu¡er (50 mM Tris-HCl (pH
7.8), 10 mM MgCl2, 10 mM DTT, 1 mM ATP, 50 Wg/ml BSA) to
which 1 Wl of T4 DNA ligase (New England BioLabs, Beverly, MA)
was added and the mixture was incubated overnight at 16‡C. The
ligated plasmid was transformed into competent Escherichia coli
DH5K which was spread onto carbenicillin agar plates. After over-
night incubation each colony was expanded into 5 ml LB broth cul-
ture medium, from which plasmids were recovered and sequenced by
a dideoxy termination method [17] using the AutoRead Sequencing
Kit II (Pharmacia/LKB, Uppsala, Sweden) and ALF DNA Sequencer
II (Pharmacia/LKB). Deletion mutants con¢rmed to contain the bp
3301 to +12, bp 3267 to +12, and bp 3245 to +12 regions of the
gp91phox gene were subcloned into the KpnI and NcoI sites of lucifer-
ase expressing pGVB2 basic vector.
The GATA mutant bp 3267 to +12 luciferase reporter construct
(Fig. 4) was made by PCR ampli¢cation of the gp91phox promoter
with a mutant sequence having the TC to AG substitution at bp
3253 to 3252 as a primer. The mutant construct was veri¢ed by
DNA sequencing and subcloned into the KpnI and NcoI site of a
luciferase expressing pGVB2 vector.
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2.2. Cell culture
HL-60-C15, an eosinophil-committed subline of HL-60, a promye-
locytic leukemia cell line, was a generous gift from S.A. Fischko¡ [18].
The cells were maintained in RPMI 1640 supplemented with 10% fetal
bovine serum (Hyclone, Logan, UT), 2 mM L-glutamine (Wako Life
Science, Tokyo, Japan), 26 mM NaHCO3 (Wako Life Science) and
passaged twice a week.
2.3. Transient transfections
HL-60-C15 cells were transiently transfected by electroporation us-
ing a Bio-Rad gene pulser II (Bio-Rad Laboratories, Hercules, CA) as
follows. Cells (5U106) in 300 Wl of HEPES-bu¡ered (25 mM, pH 7.4),
serum-free RPMI 1640 medium were put in a 4-mm gapped electro-
poration cuvette (Bio-Rad) containing 10 Wg of gp91phox promoter
¢re£y luciferase plasmid and 0.05 Wg of CMV promoter/enhancer
renilla luciferase plasmid (pRL-CMV) (Promega, Madison, WI) as
an internal control. The cells in the cuvette were gently pipetted for
mixing, kept at room temperature for 15 min, and electroporated at
310 V with a capacitance of 950 WF. The cells were kept on ice for
15 min and grown in 8 ml of RPMI 1640 supplemented with 10% FBS
(Hyclone) and 2 mM glutamine at 37‡C under 5% CO2-95% air. After
10 h of incubation, cells were washed twice with Ca2/Mg2-free
phosphate-bu¡ered saline, lysed in 100 Wl of 1UPLB (Passive lysis
bu¡er) (Promega) by a 10 s sonication on ice and allowed to lyse
completely for 20 min. Solubilized cell lysates were collected by cen-
trifugation at 21 000Ug for 2 min and an aliquot of 10 Wl lysate was
used for simultaneous assays of the two luciferase activities using the
Dual-Luciferase Reporter Assay System (Promega) and a luminome-
ter, Berthold Multi-Biolumat LB 9505C (Berthold, Wildbad, Ger-
many). The reporting activity of ¢re£y luciferase was normalized by
a simultaneously assayed renilla luciferase activity. Each mean value
of the reporter activity was obtained from at least three independent
triplicate values using at least two di¡erent preparations of plasmid
DNA (Qiagen Plasmid Maxi Kit, Qiagen, Valencia, CA). Statistical
signi¢cance was determined by Student’s t-test.
2.4. Preparation of nuclear extracts
Nuclear extracts were prepared from culture cells essentially accord-
ing to the method of Edgar Schreiber et al. [19] with minor modi¢-
cations. Brie£y, 107 cells in a suspension of 400 Wl of bu¡er A (10 mM
HEPES, pH 7.9, 10 mM KCl, 1 mM EDTA, 0.1 mM EGTA, 1 mM
DTT, 0.5 mM phenylmethylsulfonyl £uoride (PMSF), 2 Wg leupeptin,
2 Wg aprotinin, 10 Wg E-64, 10 Wg dichloroisocoumarin, and 10 Wg
pepstatin A (Sigma, St. Louis, MO)) was allowed to swell on ice for
15 min, 25 Wl of a 10% solution of Nonidet NP-40 (Nacalai Tesque,
Kyoto) was added to the suspension, which was vigorously vortexed
for 10 s and centrifuged for 1 min (12 000Ug, 4‡C). The precipitate
obtained was resuspended in 100 Wl of cold bu¡er C (20 mM HEPES,
pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM
PMSF, 2 Wg leupeptin, and 2 Wg aprotinin), rotated for 30 min at 4‡C,
and centrifuged for 5 min (21 000Ug, 4‡C). Nuclear extracts recovered
as supernatant were divided into aliquots (50 Wl each) and immedi-
ately frozen to 380‡C. Protein concentration was assayed spectro-
scopically using the Bio-Rad protein assay.
2.5. Electrophoretic mobility shift assay (EMSA)
Sense and antisense oligonucleotide (oligo) probes dissolved in
400 Wl of annealing bu¡er (100 mM Tris-HCl, pH 8.0, 1.5 mM
NaCl, 10 mM EDTA) were denatured at 100‡C for 5 min and an-
nealed at room temperature for 2 h. The duplex was labeled with [K-
32P]ddATP (3000 Ci/ml) using terminal deoxynucleotidyl transferase
(TdT) (3P-END labeling kit, Amersham International, Amersham,
UK). Five Wg of nuclear extracts was incubated on ice for 15 min
with or without one of 300-fold molar excess cold competitors in 20 Wl
of binding reaction mixture (20 mM Tris-HCl, pH 7.6, 50 mM KCl,
1 mM DTT, 1 mM MgCl2, 0. 2 mM EDTA, 0.01% Triton X-100, 5%
glycerol, 0.5 mM spermidine and 0.5 Wg double stranded poly(dI-dC)).
32P-labeled DNA probe (1U104 cpm) was added to the reaction mix-
ture, which was further incubated on ice for 15 min. The mixture was
loaded on 3.4% polyacrylamide in 0.4UTBE bu¡er and electropho-
resed at 4‡C under a constant current of 25 mA. The gel was dried
and analyzed with a GS-250 Molecular Image Analyzer (Bio-Rad).
Antibody supershift assay was performed using 4 Wg of mono-spe-
ci¢c polyclonal antibodies raised against the carboxy-terminal of ei-
ther GATA-1, GATA-2 or GATA-3 (Santa Cruz Biotechnology, San-
ta Cruz, CA), or control goat IgG. Before addition of the radiolabeled
probe, the nuclear extract was incubated with an antibody on ice for
1 h and electrophoresis was done as mentioned above.
Following are sequences of the upper strands of double stranded
oligos used in EMSAs as labeled and unlabeled probes: oligo 1 (#1),
bp 3301 to 3257 of gp91phox promoter; 5P-AGTTATTTCACTGTG-
TAAAATACATCCCTTAAAATGCACTGTTAT-3P ; #2, bp 3260
to 3240 of gp91phox promoter, 5P-TTATTTATCTCTTAGTTGTA-
G-3P ; #3, bp 3250 to 3230 of gp91phox promoter, 5P-CTTAGTTG-
TAGAAATTGGTTT-3P ; #4, bp 3260 to 3240 of gp91phox promoter
containing a two-point mutation (indicated in bold face), at a GATA
consensus site, 5P-TTATTTAAGTCTTAGTTGTAG-3P. We used oth-
er oligos, one was the GATA consensus oligo from the human T-cell
receptor N gene [20] and the other its GATA-mutant one: #5, 5P-
CACTTGATAACAGAAAGTGATAACTCT-3P, and #6, 5P-CACT-
TCTTAACAGAAAGTCTTAA CTCT-3P (mutated nucleotides
shown in bold face).
3. Results and discussion
To determine the eosinophil-speci¢c regulatory element in
the human gp91phox gene promoter region, eosinophil-com-
mitted HL-60-C15 cells were transiently transfected with a
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Fig. 1. Functional analysis of human gp91phox promoter constructs in eosinophil-committed HL-60-C15 cells. 5P deletion mutants of the
gp91phox promoter in the pGVB2 luciferase expression vector schematically shown on the left were transiently transfected into HL-60-C15 cells
and reported luciferase activities were determined as described in Section 2. Bar is one S.E.M.
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series of 5P-promoter deletion constructs. The deletion of the
promoter sequence from bp 3301 to 3268 did not change any
reporter activity (Fig. 1). But an 83% increment in promoter
activity was obtained on further deletion down to bp 3246.
These results indicate the sequence from bp 3267 to 3246 of
the gp91phox gene is a negative element for the expression of
the gp91phox gene.
To determine a nuclear protein(s) binding to the negative
element of the gp91phox promoter, EMSAs were performed
using nuclear protein extracts from HL-60-C15 cells. First,
we used two overlapping gp91phox oligo promoter fragments,
#1 and #2, as labeled probes that covered the negative ele-
ment (Fig. 2A). No speci¢c DNA binding protein complexes
were found when #1 (Fig. 2B) but #2 (Fig. 2C, lane 1, in-
dicated by an arrow) was used as a probe. As computer anal-
ysis revealed the GATA consensus site (5P-TTATCTC-3P) cen-
tered at bp 3253 (Fig. 2A), we used #3 having no GATA site
and #5 derived from the T-cell receptor N gene containing
GATA consensus sequences [20] as competitors with the ex-
pectation that the speci¢c DNA binding protein(s) might be
GATAs (Fig. 2C, lanes 4 and 5 respectively). As shown in
Fig. 2C, the DNA binding protein(s) was GATA(s) because
the complex was de¢nitely inhibited by an excess amount of
the wild competitor, #2 (lane 2) and also by #5 (lane 5) but
not by an excess amount of #1 (lane 3) or #3 (lane 4). Oligos
#4 and #6, which are GATA-mutant versions of #2 and #5,
respectively, failed to inhibit complex formation (lanes 6 and
7). On the other hand, if #4 was used as a probe, no complex
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Fig. 2. Detection of DNA binding protein(s) speci¢cally recognizing the negative element of the gp91phox promoter (bp 3267 to 3246) in HL-
60-C15 cells. A: Oligo DNA fragments (oligo) of the human gp91phox promoter region (#1^#4) and GATA consensus oligos (#5 and #6) of
the T-cell receptor N gene are schematically shown. The negative element of the gp91phox promoter region (data from Fig. 1) is in bold face.
Oligo #4 is a GATA mutant of #2. B: EMSAs were performed using oligo #1 as a labeled probe and 5 Wg of nuclear extracts from HL-60-
C15 cells in the absence (lane 1) or presence of a molar excess of cold competitors (lane 2, #1; lane 3, #2) as described in Section 2. C: EM-
SAs were performed using #2 (lanes 1-7) or #4 (lane 8) as probes and the nuclear extracts of HL-60-C15 cells as in B in the absence (lanes 1,
8) or presence of one of the following fragments as a competitor: #2 (lane 2), #1 (lane 3), #3 (lane 4), #5 (lane 5), #4 (lane 6) and #6 (lane7).
The arrow indicates the speci¢c DNA-protein complex and the asterisks indicate non-speci¢c complexes.
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was found at the level of the speci¢c complex formed by #2
(lane 8). Therefore, we speculated that the GATA consensus
site centered at bp 3253 is important for the negative regu-
lation of the gp91phox gene in HL-60-C15 cells, and the GATA
binding protein(s) might be trans-acting factor(s).
To identify a nuclear protein(s) speci¢cally binding to the
GATA consensus site in HL-60-C15 cells, EMSAs were per-
formed using bp 3260 to 3240 (#2) as the labeled probe and
mono-speci¢c antibodies against human GATA-1, GATA-2
and GATA-3 (Fig. 3). The GATA consensus sequence-speci¢c
complex is indicated by an arrow (lane 1). Neither supershift
nor inhibition of the complex formation by anti-GATA-1
(lane 3) and anti-GATA-2 antibodies (lane 4) was observed
as in the case of control goat IgG (lane 6). But the formation
of the complex was almost completely inhibited by anti-
GATA-3 antibody (lane 5). These results indicate that
GATA-3, but not GATA-1 or GATA-2, binds to the
GATA consensus site of the gp91phox promoter in HL-60-
C15 cells.
From the above data, we have shown in HL-60-C15 cells
that GATA-3 is the protein that speci¢cally binds to the
GATA consensus site (bp 3256 to 3250) in the negative
element of the gp91phox gene. Therefore GATA-3 was sup-
posed to be a repressor for the expression of the gene. To
determine whether GATA-3 is actually a repressor or not,
we transiently transfected the cells with either the wild bp
3267 to +12 promoter construct or the GATA-mutant one
in which the TC to AG substitution was introduced to the
GATA consensus site because the substitution made #2 lose
its binding activity to GATA-3 (Fig. 2C, lane 8). The mutant
construct exhibited promoter activity 81% higher than the
wild construct did (Fig. 4B, P6 0.01). The activity is compar-
able to that of the bp 3245 to +12 construct (Fig. 1). These
results indicate that GATA-3 is the repressor for gp91phox
gene expression in eosinophilic HL-60-C15 cells.
To date, GATA-3 mRNA has been reported only in periph-
eral eosinophils but not in other gp91phox-expressive cell line-
ages (neutrophils, macrophage or B lymphocytes) [15,16]. In
this study, we have shown that GATA-3 expressed in eosino-
phil-committed HL-60-C15 cells binds to the gp91phox pro-
moter and represses gene expression. Therefore, GATA-3
acts as an eosinophil lineage-speci¢c repressor of the
gp91phox gene. Though mRNAs for GATA-1 and GATA-2
are present in HL60-C15 cells [15], we could not detect these
factors possibly because of too low contents of them to be
detected by EMSA.
GATA-3 has been reported as a repressor in the human
erythropoietin (Epo) gene [21] and the 17L-hydroxysteroid
dehydrogenase type 1 gene [22]. Repression mechanisms of
GATA-3 can be classi¢ed into two groups depending on the
competition with TBP. In one mechanism, GATA-3 competes
with TBP to bind at the GATA site lying in place of the
TATA box in TATA-less genes [23]. In these cases, a
GATA sequence, but not its inverted one, lies on an upper
strand. In the other mechanism, GATA-3 binds to a GATA
site lying far from the TATA box in the promoter, and in-
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Fig. 4. Comparative activities of wild type gp91phox promoter con-
struct and its GATA-mutant version in HL-60-C15 cells. A: Wild
type and GATA-mutant gp91phox promoter luciferase constructs are
schematically shown. Mutated AG are shown in bold face. B: The
wild bp 3267 to +12 pGVB2 ¢re£y luciferase construct and its
GATA-mutant form were transiently transfected in HL-60-C15 cells,
and luciferase activities were detected as described in Section 2. Bar
is one S.E.M.
Fig. 3. Identi¢cation of protein in HL-60-C15 cells that binds to the
GATA binding site in the human gp91phox promoter. Using the bp
3260 to 3240 gp91phox promoter fragment (#2) as a probe EMSA
was performed as described in Section 2. Nuclear protein extracts
from HL-60-C15 cells were preincubated with goat antibodies
against GATAs. An arrow indicates a speci¢c DNA-protein com-
plex.
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hibits gene expression without competing TBP. The latter
mechanism has de¢nitely been demonstrated in the 17L-hy-
droxysteroid dehydrogenase type 1 gene [22]. The GATA-3
repression mechanism for the human gp91phox gene is consis-
tent with the second one but not the ¢rst one because the gene
has a TATA box, the GATA consensus site is inverted and
located far from its core promoter.
A few other transcriptional factors have been proposed as
repressors of the gp91phox gene in non-eosinophilic myeloid
cells. Human CDP binds to multiple sites in the promoter,
competes with CP1, and is downregulated in the course of
phagocytic di¡erentiation allowing expression of the gene
[24]. IRF-2 is supposed to bind to the site centered at bp
3230 in competition with TF1phox, an activator [12].
GATA-3 is unlikely to compete with other factors on the
site centered at bp 3253 in HL-60-C15 cells because other
factors binding to the same site were not found.
In conclusion, we have identi¢ed GATA-3 as the ¢rst de-
¢ned eosinophilic lineage-speci¢c repressor of human gp91phox
gene. GATA-3 may regulate gp91phox gene expression to an
optimal level with a possible eosinophil-speci¢c activator for
su⁄cient killing of invading parasites and for avoiding un-
wanted toxic e¡ects of reactive oxygen species. The GATA
consensus site identi¢ed should be an ideal target for transient
gene therapy for increasing eosinophil-speci¢c expression of
gp91phox to achieve potential killing of parasites.
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